Tag Archives: PFE

Sarepta Therapeutics: Backing A Cure For Duchenne Muscular Dystrophy

Succeeding 13 years of R&D with a commercial-level rare disease drug, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) tees up to deliver on the latter half of its promise to provide the world with a DMD cure for sufferers that may be amenable to Exon 51 skipping, and otherwise. A result that would facilitate the first cure for DMD and sizable growth potential.

In 2016, Sarepta Therapeutics,....More>>>

10 Biotech Stocks With Game-Changing Dates in Q3

For some investors, they’ve created small fortunes. For others, they’ve brought nothing but misery. For all investors, though, there’s no denying the fact that biotech stocks have kept things interesting if only because they can always supply a binary even traders can treat like a coin toss. The third quarter of 2017 isn’t going to be any different.

To....More>>>

Vitality Biopharma Adds a Regulatory Heavyweight as an Advisor

The management of regulatory affairs essentially contributes to the overall success of new drug development – both at early pre-marketing stages and at all times post-marketing. This means that a biotech or pharma company’s regulatory affairs personnel will be heavily involved in all stages of new drug development both prior to and after an FDA approval. 

That’s....More>>>

Why 3D Printing and Biotech Will Be Good Bets in 2017

Some analysts cite Hillary Clinton’s continued criticism of drug prices as a cause for a slump in biotech during the U.S. presidential campaign, but with the election behind us, many biotech enterprises saw at least a 9% increase due to Donald Trump’s victory.

Two companies in the biotech space entering the first quarter of 2017 may be in a position for their products,....More>>>

Pfizer Near A Technical Breakout

Pfizer (NYSE:PFE) has been gaining a lot of momentum recently with its share price having risen almost 7% since the 24th of January. The stock has been riding the biotech wave since the complex bottomed back in November but also has traded strongly since it announced its fourth quarter results at the end of January. Although the company missed earnings expectation in Q4 due to established....More>>>